STOCK TITAN
  1. Home
  2. News
  3. NVAX

Novavax Inc - NVAX STOCK NEWS

Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.

Novavax Inc. (Nasdaq: NVAX) is a clinical-stage biotechnology company dedicated to developing vaccines to prevent infectious diseases. Based in Gaithersburg, Maryland, with facilities in Rockville, Maryland, and Uppsala, Sweden, Novavax employs over 300 professionals focused on innovation in vaccine development.

Novavax leverages its proprietary recombinant nanoparticle technology and Matrix-M™ adjuvant to create vaccines that stimulate strong immune responses. The company's product pipeline includes vaccine candidates for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza, and Ebola virus. Additionally, their pipeline includes preclinical programs targeting various infectious diseases.

Recently, Novavax has made significant strides in COVID-19 vaccine development. The company announced that its Nuvaxovid™ XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) received Emergency Use Listing (EUL) from the World Health Organization (WHO). This listing expedites the regulatory approval process, enabling broader global distribution. The vaccine is also authorized in the U.S. and the European Union and is under review in other markets.

Novavax's updated COVID-19 vaccine can be stored at temperatures between 2 to 8 degrees Celsius and has a 12-month shelf life, simplifying logistics and reducing waste. This vaccine has shown efficacy against multiple variants, including BA.2.86, EG.5.1, and XBB.1.16.6.

In addition to their COVID-19 efforts, Novavax has entered a co-exclusive licensing agreement with Sanofi to enhance the distribution of their standalone adjuvanted COVID-19 vaccine and develop combination vaccines. This partnership highlights the company's commitment to leveraging its technology to address global health challenges.

Financially, Novavax has shown a strong performance with updated financial guidance for 2024. With over $1 billion in potential contract value for advance purchase agreements, Novavax is well-positioned to deliver on its commitments while focusing on expanding its product portfolio.

Overall, Novavax Inc. represents a significant player in the biotechnology sector, continuously pushing the boundaries of vaccine development to address pressing global health issues.

News

Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024

Rhea-AI Summary
Novavax to present updated data on COVID-19 vaccine at World Vaccine Congress 2024, showcasing robust antibody responses. The company will also discuss its influenza and COVID-19-Influenza Combination vaccine candidates, with a Phase 3 trial planned for later in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
covid-19
-
News

Novavax to Participate in TD Cowen's 44th Annual Health Care Conference

Rhea-AI Summary
Novavax, Inc. (NVAX) to participate in TD Cowen's 44th Annual Health Care Conference, featuring fireside chat and investor meetings on March 6, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.11%
Tags
conferences
-
News

Novavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Rhea-AI Summary
Novavax, Inc. (NVAX) achieved revenues of $291 million in Q4 2023 and $1.0 billion for full year 2023. The company is progressing towards a Phase 3 COVID-19-Influenza Combination vaccine trial in 2024 with a potential 2026 launch. Novavax rescaled its global footprint with a 30% headcount reduction compared to Q1 2023, settled with Gavi, and provided a revenue guidance of $800 million to $1 billion for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.74%
Tags
earnings
News

Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement

Rhea-AI Summary
Novavax, Inc. (NVAX) and Gavi, the Vaccine Alliance, settle the 2021 Advance Purchase Agreement related to NVX-CoV2373, Novavax's COVID-19 vaccine prototype. Novavax makes a $75 million initial payment to Gavi and agrees to deferred payments of $80 million annually through 2028, totaling up to $400 million. The agreement aims to ensure equitable access to vaccines for vulnerable populations in lower income countries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.61%
Tags
covid-19
-
News

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights on February 28, 2024

Rhea-AI Summary
Novavax, Inc. (NVAX) will announce its Q4 and full-year 2023 financial results and operational highlights on February 28, 2024. The conference call details and webcast information are provided for participants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
conferences earnings
-
News

Novavax to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Novavax, a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, announced its participation in the 42th Annual J.P. Morgan Healthcare Conference. The conference will include a presentation and Q&A session on January 8, 2024, with John C. Jacobs, President and Chief Executive Officer, as a participant. A replay of the recorded presentation and Q&A will be available on the company's website for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
conferences
News

Novavax's Updated COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan

Rhea-AI Summary
Novavax, Inc. (NVAX) announced that the Taiwan Food and Drug Administration has granted emergency use authorization for Nuvaxovid™ XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) for active immunization to prevent COVID-19 in individuals aged 12 and older. The updated vaccine will be widely available at vaccination centers across Taiwan. The authorization was based on non-clinical data showing that Novavax's updated COVID-19 vaccine induced functional immune responses for various variants. Novavax's updated COVID-19 vaccine is also authorized in the U.S., the European Union, Canada, and by the World Health Organization, and is under review in other markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
acquisition covid-19
-
News

Novavax's Updated COVID-19 Vaccine Now Authorized in Canada

Rhea-AI Summary
Novavax, Inc. (Nasdaq: NVAX) announces expanded authorization for Nuvaxovid™ XBB.1.5 Vaccine in Canada for individuals aged 12 and older. The vaccine targets immune-evasive variants of SARS-CoV-2 and has shown to induce functional immune responses against multiple variants. Novavax's updated COVID-19 vaccine is also authorized in the U.S., the European Union, and by the WHO, and is under review in other markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
covid-19
-
News

Novavax's Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health Organization

Rhea-AI Summary
Novavax, Inc. (NVAX) announced that its Nuvaxovid™ XBB.1.5 COVID-19 Vaccine has been granted Emergency Use Listing (EUL) by the World Health Organization for active immunization to prevent COVID-19 in individuals aged 12 and older. The vaccine can be stored at 2 to 8 degrees Celsius and has a 12-month shelf life. The EUL was based on non-clinical data showing that the vaccine induced functional immune responses against various COVID-19 variants. The vaccine is authorized in the U.S. and the European Union, and is under review in other markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.95%
Tags
covid-19
News

Novavax Makes Changes to Executive Leadership Team to Enhance Focus on Delivery of Strategic Priorities

Rhea-AI Summary
Novavax, Inc. (Nasdaq: NVAX) announces a new organizational structure for its executive leadership team aimed at enhancing focus on strategic priorities and continuing the evolution of the Company's scale and structure. John Trizzino appointed as President and Chief Operating Officer to lead commercial, CMC, and regulatory functions. Mark Casey to join as Chief Legal Officer and Corporate Secretary.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
management

FAQ

What is the current stock price of Novavax (NVAX)?

The current stock price of Novavax (NVAX) is $8.04 as of November 21, 2024.

What is the market cap of Novavax (NVAX)?

The market cap of Novavax (NVAX) is approximately 1.3B.

What is Novavax Inc. known for?

Novavax Inc. is known for developing innovative vaccines to prevent a broad range of infectious diseases using its proprietary recombinant nanoparticle technology and Matrix-M™ adjuvant.

Where is Novavax Inc. headquartered?

Novavax Inc. is headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland, and Uppsala, Sweden.

What recent achievements has Novavax made?

Recently, Novavax's Nuvaxovid™ XBB.1.5 COVID-19 Vaccine received Emergency Use Listing (EUL) from the World Health Organization (WHO), facilitating global distribution.

What is the storage requirement for Novavax's COVID-19 vaccine?

Novavax's COVID-19 vaccine can be stored at temperatures between 2 to 8 degrees Celsius and has a 12-month shelf life.

Who are Novavax’s main partners?

Novavax has partnered with Sanofi to enhance the distribution of its standalone adjuvanted COVID-19 vaccine and develop combination vaccines.

What are the key products in Novavax's pipeline?

Novavax’s product pipeline includes vaccines for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza, and Ebola virus, as well as preclinical programs for other infectious diseases.

How does Novavax’s Matrix-M™ adjuvant work?

The Matrix-M™ adjuvant enhances the immune response by stimulating the entry of antigen-presenting cells at the injection site and enhancing antigen presentation in local lymph nodes.

What financial performance is expected from Novavax in 2024?

Novavax has provided financial guidance for 2024, with over $1 billion in potential contract value for advance purchase agreements, indicating a strong financial outlook.

Is Novavax's COVID-19 vaccine effective against variants?

Yes, Novavax's COVID-19 vaccine has shown efficacy against multiple variants, including BA.2.86, EG.5.1, and XBB.1.16.6.

What is the significance of Novavax's partnership with Sanofi?

The partnership with Sanofi enhances the distribution of Novavax's COVID-19 vaccine and supports the development of combination vaccines, highlighting Novavax's commitment to global health initiatives.

Stock NVAX logo
Novavax Inc

Nasdaq:NVAX

NVAX Rankings

#2335 Ranked by Market Cap
N/A Ranked by Dividends

NVAX Stock Data

1.31B
153.17M
4.38%
60.12%
24.97%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
GAITHERSBURG